Morgan Stanley lowered the firm’s price target on Cytek Biosciences (CTKB) to $4 from $7 and keeps an Equal Weight rating on the shares post the Q2 report. The firm says recurring revenue strength offset weakness in the company’s instrument segment. It believes Cytek’s visibility remains limited.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTKB:
- Cytek Biosciences Earnings Call Reveals Mixed Outlook
- Cytek Biosciences: Q2 2025 Financial Performance Overview
- Cytek Biosciences Faces Market Challenges and Uncertain Growth Prospects Leading to Hold Rating
- Cytek Biosciences reports Q2 EPS (4c), consensus (1c)
- Cytek Biosciences narrows FY25 revenue view to $196M-$200M from $196M-$210M